Celgene fails to win NICE endorsement for Revlimid

The U.K.'s National Institute for Health and Clinical Excellence ruled that Revlimid, a myeloma drug from Celgene, is not cost effective enough to be covered by the National Health Service. Charitable groups are urging the Department of Health to work with Celgene so that NHS patients can have access to the medicine, which has been shown to prolong the lives of people with the bone marrow cancer by as long as three years.

View Full Article in:

Telegraph (London) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC